Adaptive Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Adaptive Biotechnologies Corp
ADPT Stock  USD 15.64  0.22  1.39%   
Analyzing historical trends in various income statement and balance sheet accounts from Adaptive Biotechnologies' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adaptive Biotechnologies' valuation are summarized below:
Gross Profit
111.8 M
Profit Margin
(0.21)
Market Capitalization
2.4 B
Enterprise Value Revenue
8.2719
Revenue
277 M
There are currently one hundred twenty fundamental signals for Adaptive Biotechnologies Corp that can be evaluated and compared over time across rivals. All traders should validate Adaptive Biotechnologies' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.9 B in 2026. Enterprise Value is likely to gain to about 4 B in 2026

Adaptive Biotechnologies Total Revenue

151.97 Million

Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 17.5 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 8.45, Dividend Yield of 0.0 or PTB Ratio of 11.82. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
  
Build AI portfolio with Adaptive Stock
Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Adaptive Biotechnologies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets784.4 M620.3 M567.4 M
Slightly volatile
Short and Long Term Debt Total76.4 M80.4 M339 M
Slightly volatile
Other Current Liabilities20.2 M28.4 M13.6 M
Slightly volatile
Total Current Liabilities87.6 M112.8 M57.9 M
Slightly volatile
Other Liabilities125.4 M211.6 M83.5 M
Slightly volatile
Property Plant And Equipment Net107.8 M108.5 M64.6 M
Slightly volatile
Current Deferred Revenue56.4 M64 M37 M
Slightly volatile
Accounts Payable5.2 M8.4 M3.8 M
Slightly volatile
Cash70.2 M43.1 M83.1 M
Pretty Stable
Non Current Assets Total319 M294 M237.3 M
Slightly volatile
Non Currrent Assets Other3.5 M6 M2.1 M
Slightly volatile
Other Assets6.7 M4 M4.1 M
Pretty Stable
Long Term Debt271.2 K302.4 K333 K
Slightly volatile
Cash And Short Term Investments418.3 M255.6 M297.7 M
Slightly volatile
Net Receivables50.4 M48 M18.1 M
Slightly volatile
Good Will95.2 M107.1 M116.9 M
Slightly volatile
Common Stock Total Equity10.3 K16.1 K6.9 K
Slightly volatile
Common Stock Shares Outstanding145.8 M151.7 M122.1 M
Slightly volatile
Short Term Investments321.7 M200.5 M212.4 M
Slightly volatile
Long Term Debt Total44.2 M42.1 M18.2 M
Slightly volatile
Liabilities And Stockholders Equity784.4 M620.3 M567.4 M
Slightly volatile
Non Current Liabilities Total265.7 M215 M417.7 M
Slightly volatile
Capital Surpluse910.1 M1.6 B612.9 M
Slightly volatile
Inventory12.7 M9.7 M8.7 M
Slightly volatile
Other Current Assets10.9 M13 M7.2 M
Slightly volatile
Other Stockholder Equity1.1 B1.7 B642.3 M
Slightly volatile
Total Liabilities329.4 M303.2 M472.7 M
Slightly volatile
Property Plant And Equipment Gross130 M209.5 M81.3 M
Slightly volatile
Total Current Assets465.4 M326.3 M330.2 M
Slightly volatile
Non Current Liabilities Other135.5 M152.3 M67.6 M
Slightly volatile
Net Working Capital377.8 M213.6 M272.3 M
Slightly volatile
Intangible Assets2.9 M3.1 M11.1 M
Slightly volatile
Common Stock11.6 K16.1 K7 K
Slightly volatile
Property Plant Equipment48.6 M96 M39.7 M
Slightly volatile
Capital Stock13 K16.1 K7.1 K
Slightly volatile
Capital Lease Obligations101.3 M102.8 M63.9 M
Slightly volatile

Adaptive Biotechnologies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income17.5 M16.7 M5.9 M
Slightly volatile
Depreciation And Amortization14.4 M22.1 M10.7 M
Slightly volatile
Selling General Administrative62.2 M72.7 M40.1 M
Slightly volatile
Selling And Marketing Expenses73.3 M94.6 M46.5 M
Slightly volatile
Total Revenue152 M277 M97.9 M
Slightly volatile
Gross Profit215.9 M205.6 M71.3 M
Slightly volatile
Other Operating Expenses296.3 M334.1 M193.8 M
Slightly volatile
Research Development105.2 M93.8 M70 M
Slightly volatile
Cost Of Revenue49.7 M71.4 M33.3 M
Slightly volatile
Total Operating Expenses246.6 M262.7 M160.5 M
Slightly volatile
Reconciled Depreciation14.3 M22.1 M10.7 M
Slightly volatile
Non Operating Income Net Other3.3 M3.7 M5.5 M
Slightly volatile

Adaptive Biotechnologies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock6.7 M7.1 M63.8 M
Very volatile
Stock Based Compensation37.3 M61.7 M24.7 M
Slightly volatile
Begin Period Cash Flow95.4 M78.2 M64.9 M
Slightly volatile
Depreciation16.3 M22.1 M11.6 M
Slightly volatile
Other Non Cash Items9.8 M10.3 M13.8 M
Slightly volatile
Capital Expenditures4 M4.2 M9.2 M
Slightly volatile
Total Cash From Financing Activities206.1 K216.9 K69.3 M
Very volatile
End Period Cash Flow71 M45.7 M83.8 M
Pretty Stable
Change To Netincome68.2 M64.9 M26.6 M
Slightly volatile
Change To Liabilities6.1 M6.4 M19.3 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8.458.895967.109
Slightly volatile
Days Sales Outstanding47.0366.371255.7113
Slightly volatile
Stock Based Compensation To Revenue0.180.270.2184
Slightly volatile
Capex To Depreciation0.210.220.7526
Pretty Stable
EV To Sales9.179.654573.5313
Slightly volatile
Inventory Turnover7.637.26673.9986
Slightly volatile
Days Of Inventory On Hand47.7250.2291109
Slightly volatile
Payables Turnover7.4411.03438.6504
Slightly volatile
Sales General And Administrative To Revenue0.460.26250.4193
Very volatile
Research And Ddevelopement To Revenue0.320.33850.7653
Slightly volatile
Capex To Revenue0.02240.02350.0927
Very volatile
Cash Per Share1.421.4962.2863
Pretty Stable
Days Payables Outstanding47.333.078644.3721
Pretty Stable
Intangibles To Total Assets0.240.23540.2822
Slightly volatile
Current Ratio6.363.33857.4559
Slightly volatile
Receivables Turnover7.675.49946.9776
Pretty Stable
Capex Per Share0.02130.02240.0695
Pretty Stable
Revenue Per Share1.921.82560.7894
Slightly volatile
Interest Debt Per Share2.051.9273.2991
Slightly volatile
Debt To Assets0.550.54720.9341
Slightly volatile
Operating Cycle191117171
Very volatile
Days Of Payables Outstanding47.333.078644.3721
Pretty Stable
Ebt Per Ebit0.781.04090.9563
Pretty Stable
Long Term Debt To Capitalization0.520.541.2098
Slightly volatile
Total Debt To Capitalization0.630.56191.0268
Slightly volatile
Quick Ratio6.173.22937.2636
Slightly volatile
Net Income Per E B T0.81.00070.9881
Slightly volatile
Cash Ratio0.740.7842.4769
Slightly volatile
Cash Conversion Cycle14383.5217126
Very volatile
Days Of Inventory Outstanding47.7250.2291109
Slightly volatile
Days Of Sales Outstanding47.0366.371255.7113
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.221.191.104
Slightly volatile
Fixed Asset Turnover3.893.70672.3529
Pretty Stable
Debt Ratio0.550.54720.9341
Slightly volatile
Price Sales Ratio8.458.895967.109
Slightly volatile
Asset Turnover0.570.54020.193
Slightly volatile
Gross Profit Margin0.540.74240.6292
Slightly volatile

Adaptive Biotechnologies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.9 B2.8 B3.8 B
Slightly volatile
Enterprise Value4 B3.1 B4.1 B
Slightly volatile

Adaptive Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue64 M56.4 M
Total Revenue277 M152 M
Cost Of Revenue71.4 M49.7 M
Stock Based Compensation To Revenue 0.27  0.18 
Sales General And Administrative To Revenue 0.26  0.46 
Research And Ddevelopement To Revenue 0.34  0.32 
Capex To Revenue 0.02  0.02 
Revenue Per Share 1.83  1.92 
Ebit Per Revenue(0.21)(0.22)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY